A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Clinical trial NCT03992339 · COMPLETED
Trial details
- NCT number
- NCT03992339
- Sponsor
- Antengene Corporation
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-09
- Primary completion
- 2023-05-31
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.